A phase 1 trial found a personalised NeoVax vaccine with nivolumab feasible and acceptably safe in platinum-sensitive ovarian cancer — early data, not proof.
Disclaimer: This website accepts paid content contributions. Daily moderation is not guaranteed. The owner does not promote or endorse illegal activities like gambling, CBD, casinos, or betting.
